Mega Genomics (HKSE:06667) Capex-to-Revenue : 0.01 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Mega Genomics's Capital Expenditure for the six months ended in Jun. 2024 was HK$-0.68 Mil. Its Revenue for the six months ended in Jun. 2024 was HK$115.50 Mil.

Hence, Mega Genomics's Capex-to-Revenue for the six months ended in Jun. 2024 was 0.01.

Mega Genomics Capex-to-Revenue Historical Data

The historical data trend for Mega Genomics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Capex-to-Revenue Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

0.01

0.02

0.04

0.24

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Revenue	Get a 7-Day Free Trial				0.01	0.09	0.13	0.45	0.01

Competitive Comparison of Mega Genomics's Capex-to-Revenue

For the Diagnostics & Research subindustry, Mega Genomics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mega Genomics's Capex-to-Revenue falls into.

Mega Genomics Capex-to-Revenue Calculation

Mega Genomics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-39.482)	/	165.489
	=	0.24

Mega Genomics's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.681)	/	115.503
	=	0.01

Mega Genomics (HKSE:06667) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Mega Genomics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.

Executives

Dongyin Industrial (shenzhen) Co., Ltd.	2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd.	2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership)	2106 Person having a security interest in shares
Yurong Technology Limited	2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd.	2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited	2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership)	2106 Person having a security interest in shares
Guo Meiling	2101 Beneficial owner
Yu Rong	2501 Other
Lin Lin	2101 Beneficial owner
Infinite Galaxy Health Limited	2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other

Mega Genomics Headlines

No Headlines